Company Description
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology.
The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.
It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual’s immunological profiling data and provide advice on the users’ immune system.
It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions.
The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally.
The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021.
Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Jul 21, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | James Foster |
Contact Details
Address: BioCity Glasgow, Bo’Ness Road Newhouse Lanarkshire, ML1 5UH United Kingdom | |
| Phone | 44 20 7788 7414 |
| Website | viraxbiolabs.com |
Stock Details
| Ticker Symbol | VRAX |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001885827 |
| CUSIP Number | G9495L109 |
| ISIN Number | KYG9495L1251 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| James Foster | Chief Executive Officer |
| Jason Davis | Chief Financial Officer |
| Nigel McCracken | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 6-K | Report of foreign issuer |
| Dec 17, 2024 | 6-K | Report of foreign issuer |
| Dec 10, 2024 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | 6-K | Report of foreign issuer |
| Oct 23, 2024 | 6-K | Report of foreign issuer |
| Sep 30, 2024 | 6-K | Report of foreign issuer |
| Sep 30, 2024 | 424B5 | Filing |
| Aug 23, 2024 | 6-K | Report of foreign issuer |